Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light. The ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

It's a lost opportunity to promote a healthy gut microbiome, recover from treatment-related microbiota injury, and protect against GVHD," said first author Jenny Paredes, PhD, a staff scientist at ...

In the 132-patient ROCKstar study, almost three quarters of chronic GVHD patients treated with a daily oral dose of belumosudil (KD025) saw an improvement in symptoms that lasted for at least six ...

The researchers found that itacitinib resulted in low CRS grades; 22%, 78%, and 0% of patients had grades 0, 1, and 2 to 5, respectively. (HealthDay News) — For patients with haploidentical ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

But let's have a look. The now-approved treatment for acute GVHD is indicated for patients 2 months of age and up after developing steroid-refractory disease. This was based on high response rates ...

Patients undergoing allogeneic hematopoietic cell transplant (allo-HCT) had significantly better survival and a lower rate of graft-versus-host disease (GVHD) with higher levels of fiber intake.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).